已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial

托珠单抗 医学 安慰剂 间质性肺病 内科学 不利影响 胃肠病学 随机对照试验 临床终点 外科 病理 疾病 替代医学
作者
Dinesh Khanna,Celia J. F. Lin,Daniel E. Furst,Bridget K. Wagner,Mauro Zucchetto,Ganesh Raghu,Fernando J. Martínez,Jonathan Goldin,Jeffrey Siegel,Christopher P. Denton
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:205 (6): 674-684 被引量:90
标识
DOI:10.1164/rccm.202103-0714oc
摘要

Rationale: Tocilizumab, an anti-IL-6 receptor antibody, had no statistically significant effect on skin sclerosis but preserved lung function over 48 weeks in patients with early systemic sclerosis (SSc)-associated interstitial lung disease (ILD) in a phase 3 randomized controlled trial. Objectives: Assess long-term safety and efficacy of tocilizumab. Methods: Adults with diffuse cutaneous SSc for ⩽60 months and elevated acute-phase reactants, including those with ILD, received weekly placebo or tocilizumab 162 mg subcutaneously in the 48-week, double-blind period and then open-label tocilizumab from Weeks 48 to 96 (placebo-tocilizumab; continuous-tocilizumab). Measurements and Main Results: Eighty-two of 107 patients in the placebo-tocilizumab group and 85 of 105 patients in the continuous-tocilizumab group completed 96 weeks. Mean age and disease duration were 48 years and 23 months; high-resolution computed tomography revealed ILD in 61%. Mean (95% confidence interval [CI]) change in modified Rodnan skin score from baseline to week 96 was -8.4 (-10.0 to -6.8) for placebo-tocilizumab and -9.6 (-10.9 to -8.4) for continuous-tocilizumab. Mean (95% CI) change in FVC (percent predicted) from baseline to week 96 was -3.3 (-5.1 to -1.5) for placebo-tocilizumab and -0.5 (-2.4 to 1.3) for continuous-tocilizumab among completers and, in a post hoc analysis, -4.1 (-6.7 to -1.6) and -0.6 (-3.1 to 2.0), respectively, among completers with ILD (mean [95% CI] change from Weeks 48 to 96: 0.9 [-0.8 to 2.7] and -0.4 [-2.3 to 1.5], respectively). Rates per 100 patient-years of serious adverse events from Weeks 48 to 96 were 14.8 for placebo-tocilizumab and 15.8 for continuous-tocilizumab. Conclusions: Tocilizumab preserved lung function, slowing decline in FVC, in patients with SSc, including those with ILD. Long-term safety was consistent with the known safety profile of tocilizumab. Clinical trial registered with www.clinicaltrials.gov (NCT02453256).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
1秒前
芯之痕发布了新的文献求助10
2秒前
研友_VZG7GZ应助顺利秋灵采纳,获得10
2秒前
徐小树发布了新的文献求助10
3秒前
坚定的凝云完成签到 ,获得积分10
4秒前
5秒前
bkagyin应助zhantianao采纳,获得10
7秒前
徐志豪完成签到,获得积分10
7秒前
wanci应助科研通管家采纳,获得10
7秒前
SciGPT应助科研通管家采纳,获得10
7秒前
科研通AI5应助科研通管家采纳,获得10
7秒前
英俊的铭应助科研通管家采纳,获得10
7秒前
Hayat应助科研通管家采纳,获得10
7秒前
fly发布了新的文献求助10
9秒前
爱听歌凤灵完成签到 ,获得积分10
10秒前
lxl98完成签到 ,获得积分10
11秒前
12秒前
lwh104完成签到,获得积分10
13秒前
14秒前
15秒前
顺利秋灵发布了新的文献求助10
17秒前
漂亮白枫发布了新的文献求助10
17秒前
dzk完成签到,获得积分10
18秒前
asdfghjkl完成签到,获得积分20
18秒前
番茄黄瓜芝士片完成签到 ,获得积分10
18秒前
风趣的老太应助YDX采纳,获得10
21秒前
凌七发布了新的文献求助10
22秒前
王旭东完成签到 ,获得积分10
23秒前
犹豫的夏旋完成签到 ,获得积分10
23秒前
BBH完成签到,获得积分10
24秒前
Lee发布了新的文献求助10
24秒前
禾苗完成签到 ,获得积分10
27秒前
28秒前
林洁佳完成签到,获得积分10
30秒前
淡然平蓝完成签到 ,获得积分10
34秒前
西瓜刀完成签到 ,获得积分10
34秒前
领导范儿应助BBH采纳,获得10
34秒前
凌七完成签到,获得积分10
36秒前
bkagyin应助漂亮白枫采纳,获得10
41秒前
野猪大王完成签到 ,获得积分10
42秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976583
求助须知:如何正确求助?哪些是违规求助? 3520659
关于积分的说明 11204399
捐赠科研通 3257298
什么是DOI,文献DOI怎么找? 1798683
邀请新用户注册赠送积分活动 877842
科研通“疑难数据库(出版商)”最低求助积分说明 806595